AIM ImmunoTech Statistics
Total Valuation
AIM ImmunoTech has a market cap or net worth of $21.51 million. The enterprise value is $9.11 million.
| Market Cap | 21.51M |
| Enterprise Value | 9.11M |
Important Dates
The next estimated earnings date is Monday, May 13, 2024, before market open.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AIM ImmunoTech has 49.90 million shares outstanding. The number of shares has increased by 1.12% in one year.
| Shares Outstanding | 49.90M |
| Shares Change (YoY) | +1.12% |
| Shares Change (QoQ) | +0.52% |
| Owned by Insiders (%) | 8.99% |
| Owned by Institutions (%) | 8.32% |
| Float | 45.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 106.23 |
| Forward PS | n/a |
| PB Ratio | 2.10 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 45.08 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.68, with a Debt / Equity ratio of 0.07.
| Current Ratio | 1.68 |
| Quick Ratio | n/a |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -118.30% and return on invested capital (ROIC) is -291.25%.
| Return on Equity (ROE) | -118.30% |
| Return on Assets (ROA) | -97.90% |
| Return on Capital (ROIC) | -291.25% |
| Revenue Per Employee | $7,769 |
| Profits Per Employee | -$1.11M |
| Employee Count | 26 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.37% in the last 52 weeks. The beta is -0.15, so AIM ImmunoTech's price volatility has been lower than the market average.
| Beta (1Y) | -0.15 |
| 52-Week Price Change | -20.37% |
| 50-Day Moving Average | 0.43 |
| 200-Day Moving Average | 0.50 |
| Relative Strength Index (RSI) | 44.81 |
| Average Volume (30 Days) | 231,061 |
Short Selling Information
The latest short interest is 492,319, so 0.99% of the outstanding shares have been sold short.
| Short Interest | 492,319 |
| Short Previous Month | 411,867 |
| Short % of Shares Out | 0.99% |
| Short % of Float | 1.08% |
| Short Ratio (days to cover) | 2.17 |
Income Statement
In the last 12 months, AIM ImmunoTech had revenue of $202,000 and -$28.96 million in losses. Loss per share was -$0.60.
| Revenue | 202,000 |
| Gross Profit | 160,000 |
| Operating Income | -31.90M |
| Pretax Income | -28.96M |
| Net Income | -28.96M |
| EBITDA | -28.44M |
| EBIT | -28.96M |
| Loss Per Share | -$0.60 |
Balance Sheet
The company has $13.07 million in cash and $718,000 in debt, giving a net cash position of $12.35 million or $0.25 per share.
| Cash & Cash Equivalents | 13.07M |
| Total Debt | 718,000 |
| Net Cash | 12.35M |
| Net Cash Per Share | $0.25 |
| Equity / Book Value | 10.23M |
| Book Value Per Share | 0.21 |
| Working Capital | 5.90M |
Cash Flow
In the last 12 months, operating cash flow was -$21.27 million and capital expenditures $47,000, giving a free cash flow of -$21.22 million.
| Operating Cash Flow | -21.27M |
| Capital Expenditures | 47,000 |
| Free Cash Flow | -21.22M |
| FCF Per Share | -$0.44 |
Margins
Gross margin is 79.21%, with operating and profit margins of -15,791.09% and -14,337.62%.
| Gross Margin | 79.21% |
| Operating Margin | -15,791.09% |
| Pretax Margin | -14,337.62% |
| Profit Margin | -14,337.62% |
| EBITDA Margin | -14,077.72% |
| EBIT Margin | -14,337.62% |
| FCF Margin | -10,504.95% |
Dividends & Yields
AIM ImmunoTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.12% |
| Shareholder Yield | -1.12% |
| Earnings Yield | -134.97% |
| FCF Yield | -98.89% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | 202.96% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on June 11, 2019. It was a reverse split with a ratio of 1:44.
| Last Split Date | Jun 11, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:44 |
Scores
AIM ImmunoTech has an Altman Z-Score of -32.73 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -32.73 |
| Piotroski F-Score | 3 |